Johnson & Johnson has entered into a voluntary agreement with the United States government to expand access to medicines, reduce drug prices for millions of Americans and strengthen domestic pharmaceutical manufacturing. The agreement, reached with the Trump Administration, also provides an exemption from U.S. tariffs for the company’s pharmaceutical products.
The agreement supports national efforts to make medicines more affordable while reinforcing Johnson & Johnson’s long-term commitment to U.S. innovation, manufacturing and economic growth. As part of the arrangement, the company will participate in TrumpRx.gov, a direct-to-patient digital platform that will enable millions of Americans to purchase Johnson & Johnson medicines at significantly discounted rates.
U.S. patients will also gain access to medicines at prices comparable to those in other developed countries, and these same pricing standards will be extended to the Medicaid program, improving affordability for lower-income populations. The company will also continue to support federal efforts to ensure that the value of healthcare and medical innovation is more consistently recognised across developed markets worldwide.
Alongside the access and pricing commitments, Johnson & Johnson is continuing to deliver on its previously announced $55 billion investment programme to expand U.S. manufacturing, research and development and advanced technologies through early 2029. Over the past ten months, the company has already initiated billions of dollars in domestic manufacturing investments to support its goal of producing the vast majority of its advanced medicines within the United States for American patients.
Johnson & Johnson has announced two new U.S. manufacturing facilities—a next-generation cell therapy plant in Pennsylvania and a drug product manufacturing facility in North Carolina—expanding its capacity to produce advanced medicines domestically.
Construction is also underway at a $2 billion biologics facility in Wilson, North Carolina, expected to generate about 5,000 construction and manufacturing jobs, with hiring already in progress. The company has also secured a 160,000-plus square-foot biopharmaceutical site in Holly Springs, North Carolina, backed by a $2 billion investment over the next decade and projected to create around 120 jobs.
Johnson & Johnson has indicated that further U.S. investments will be announced later this year. Operating across Innovative Medicine and MedTech, the company continues to focus on developing smarter, less invasive and more personalised treatments to address complex diseases, reinforcing its role in shaping the future of healthcare in the United States and globally.
Also Read